Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Eisai stock performance snapshot
Eisai (TSE:4523) has recently drawn attention after a one-month return of about a 9% decline and a past three-month gain of roughly 4%, prompting investors to reassess its current valuation and fundamentals.
See our latest analysis for Eisai.
At a share price of ¥4,677, Eisai’s short term momentum has cooled, with a 1 month share price return of about 9% decline and year to date share price return of roughly 2% decline. At the same time, the 1 year total shareholder return sits near 19%, highlighting a gap between recent sentiment and the longer term outcome for investors.
If you are looking beyond a single pharmaceutical stock and want fresh ideas in healthcare, the next step could be to scan a curated list of 8 healthcare AI stocks
With Eisai trading at ¥4,677, a value score of 2, and a flagged intrinsic discount of about 30%, the key question is simple: is the stock still undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 6.6% Undervalued
With Eisai last closing at ¥4,677 against a narrative fair value of ¥5,009, the current share price sits below what the most followed valuation framework suggests, putting the focus firmly on the assumptions behind that gap.
Ongoing international rollout of LEQEMBI, marked by strong launches in Japan, China, and preparations for Europe, amid demographic shifts toward aging populations and rising dementia prevalence, positions Eisai for durable, long term revenue growth as it penetrates new geographies with high unmet medical need.
Analysts are incorporating steady top line expansion, firmer margins, and a richer earnings profile, all discounted at 4.812% to land on that fair value. Want to see exactly how revenue growth, profitability and the future earnings multiple fit together in this story? The full narrative spells out the key assumptions that bridge today’s price to that target.
Result: Fair Value of ¥5,009 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this relies heavily on the Alzheimer’s franchise. Any pricing cuts or safety concerns around LEQEMBI could quickly challenge the current valuation story.
Find out about the key risks to this Eisai narrative.
Another View: Multiples Paint a Richer Picture
While our intrinsic value work points to a discount, the market is asking a high price for Eisai on earnings. The stock trades on a P/E of 30.8x, compared with about 15.7x for the JP Pharmaceuticals sector and 14x for peers, and a fair ratio estimate of 26.8x. That gap suggests less margin for error if the earnings story slips.
For a closer look at how this premium stacks up and what the numbers imply for upside and downside risk, See what the numbers say about this price — find out in our valuation breakdown.
TSE:4523 P/E Ratio as at May 2026 Next Steps
Curious whether the mix of risks and rewards in this story really adds up for you personally? Act while the data is fresh and assess the trade off by checking the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
Do not stop your research with just one stock. Broaden your watchlist with targeted ideas that match your goals and help you stay informed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 4523.T.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com